about
Biologic Approaches to Treat Substance-Use DisordersNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?New directions in nicotine vaccine design and use.Scientific overview: 2013 BBC plenary symposium on tobacco addiction.Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditionsAdjuvants for vaccines to drugs of abuse and addiction.The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.Vaccination against smoking: an annotated agenda for debate. A review of scientific journals, 2001-13.Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy.Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alumBiologics to treat substance use disorders: Current status and new directionsThe next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.Current status and future prospects for the development of substance abuse vaccines.Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task.
P2860
Q28085073-34B20CAF-1CF7-416D-8D0C-34A9CAB16F4DQ28277165-F30A6605-773D-45E0-A54D-30B3181024F9Q33719424-9CD2B18B-1464-47E9-8503-D4DBBAA36C64Q34487271-FAECF5D5-19A6-4F0D-8541-0F42611978FCQ35061547-D19D46FB-2A08-4C56-A236-FD298962B6A5Q35493923-6EB34C95-67C9-4B1C-BD91-64A71559EB62Q36278801-2F93932B-5834-4446-88EB-B12F6E6650ABQ38216996-1D60F293-0C4A-44B8-B47A-F4070D7CB949Q38271498-335CA3FA-83B6-4E52-ACEF-DB316D4E3EB7Q38850703-FF916125-EDE7-41C5-900C-C4E317A319A7Q39519649-8F530B7A-4349-417E-9520-02EC46700BFBQ39556344-F7BC0070-4966-4E7D-BB21-1D21506F85C4Q39576940-6C1C9E45-1EE3-454E-8755-980AEFECDCDFQ42627924-E70E5ABD-649A-47E7-A3AF-91D23D02163EQ43076031-3AF4FAD8-FC03-4E5E-855A-E048B9CE8389Q47384878-FE9350F2-E029-4EE7-9642-315AD69DDFF3Q48737750-5789DB48-D564-4EB3-A08D-B90A8749D034
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapeutic vaccines against tobacco addiction.
@en
type
label
Therapeutic vaccines against tobacco addiction.
@en
prefLabel
Therapeutic vaccines against tobacco addiction.
@en
P2093
P2860
P356
P1476
Therapeutic vaccines against tobacco addiction.
@en
P2093
Matthew W Kalnik
Paul D Kessler
Raafat E F Fahim
P2860
P304
P356
10.1586/ERV.13.13
P577
2013-03-01T00:00:00Z